Skip to main content
. 2015 Aug 11;3(6):1353–1360. doi: 10.3892/mco.2015.620

Table II.

Distribution of the BRCA1 methylation status with different hormone and epidermal growth factor receptors.

BRCA1 methylation, n (total) BRCA1 non-methylation, n (total)


First author, year Population ER negative PR negative HER2 negative Triple-negative ER negative PR negative HER2 negative Triple-negative (Refs.)
Ignatov, 2013 European NA NA NA 43 (86) NA NA NA 22 (46) (21)
Krasteva, 2012 European 11 (23) 11 (23) 14 (17) NA   48 (112) 11 (23) 37 (53) NA (22)
Xu, 2009 European   89 (372) 135 (372) NA NA 127 (320) 135 (372) NA NA (23)
Xu, 2013 Asian 109 (285) 149 (282) 220 (279)   64 (282) 295 (830) 149 (282) 654 (810) 142 (817) (24)
Hsu, 2013 Asian 30 (77) 36 (77) 55 (77) 16 (77) 21 (61) 36 (78)   91 (138)   5 (61) (25)
Sharma, 2009 Asian 22 (27) 21 (27) 18 (27) 15 (27) 35 (74) 21 (27) 60 (74) 25 (74) (26)
Chen, 2009 Asian   55 (138)   80 (137)   98 (135)   31 (136) 127 (383)   80 (137) 298 (378)   64 (382) (27)
Jing, 2008 Asian 21 (33) 26 (33) NA NA 127 (168) 26 (33) NA NA (28)

Total refers to the total number of identified samples in BRCA1 methylation or non-methylation with the corresponding hormone receptor: ER, PR and HER2. Triple-negative, lacks expression of ER, PR and HER2 amplification. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; BRCA1, breast cancer susceptibility gene 1.